What Is SLU-PP-332?

Published August 2026 · Patriot Labs Research Team · ~14 min read

First things first — this is not a peptide

Almost everything else on this site is a peptide: a chain of amino acids joined by amide bonds, made by solid-phase synthesis, shipped as a lyophilised powder. SLU-PP-332 is not that, and anyone reading about it alongside peptides should have this cleared up before anything else.

The PubChem record for SLU-PP-332 gives a molecular formula of C₁₈H₁₄N₂O₂, a molecular weight of approximately 290.3, and the systematic name 4-hydroxy-N-[(E)-naphthalen-2-ylmethylideneamino]benzamide. Read that name apart and the molecule resolves into two aromatic pieces joined by a short nitrogen–nitrogen linker: a 4-hydroxybenzoyl group on one side, a naphthalene ring on the other, connected through an acylhydrazone. There are no amino acids in it. There is no peptide bond in the biological sense, no chain, no sequence, no secondary structure to preserve.

That distinction is not pedantry, because it changes the practical facts. Peptides are large, polar, and destroyed by gut proteases, which is why almost all published peptide work in animals uses a parenteral route, and why peptide degradation is dominated by hydrolysis, oxidation and aggregation. Small molecules like this one have the opposite problem set: they are metabolised by liver enzymes, their solubility depends on lipophilicity rather than on charge and folding, and the failure mode that matters most is first-pass metabolism rather than proteolysis. The PubChem record lists an XLogP of 3.7 for SLU-PP-332, which puts it firmly in the lipophilic, poorly-water-soluble half of chemical space — a fact that shows up again in the handling section below.

It is worth noting that this is not the only compound in the catalogue that is chemically a small molecule rather than a peptide. 5-Amino-1MQ is a small-molecule NNMT inhibitor, and NAD+ is a dinucleotide. Research catalogues organise by research area, not by chemical class, and readers get misled by that constantly.

The estrogen-related receptors, and a misleading name

SLU-PP-332 acts on three related proteins: ERRα, ERRβ and ERRγ, the estrogen-related receptors. They belong to the nuclear receptor superfamily — the same broad family as the glucocorticoid, thyroid hormone and estrogen receptors — and like all nuclear receptors they work as ligand-regulated transcription factors, binding DNA response elements and controlling the expression of target genes.

The name is the first thing that trips people up, and it deserves unpicking. The ERRs were identified through their sequence similarity to the classical estrogen receptor, particularly in the DNA-binding domain. That similarity is why they are called estrogen-related. It is not a statement that estrogen activates them, and reading the name as if it were is the single most common misunderstanding of this receptor family.

What the ERRs actually are is orphan nuclear receptors. In the nuclear receptor field, “orphan” means the endogenous activating ligand has not been identified. Harmit Ranhotra's 2015 review of ERRα in the Journal of Receptor and Signal Transduction Research puts this plainly: it is presently unknown which endogenous hormones or ligands activate ERRα, and the receptor nevertheless regulates a large set of genes whose products participate in metabolic pathways. The 2026 paper from Thomas Burris's group in the Journal of Pharmacology and Experimental Therapeutics uses the same framing, describing ERRα, ERRβ and ERRγ as orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle.

So if no hormone switches them on, what sets their activity? The answer in the standard account is coactivators, and principally PGC-1α. Richard Scarpulla's 2011 review in Biochimica et Biophysica Acta describes the PGC-1 family — PGC-1α, PGC-1β and PRC — as regulated coactivators occupying a central role in the transcriptional control of mitochondrial biogenesis and respiratory function, and names ERRα specifically as one of the transcription factors they target, alongside NRF-1 and NRF-2. The same review notes that PGC-1 activity is itself modulated by the cellular energy sensors AMPK and SIRT1.

That is the architecture worth carrying forward. The ERRs sit at a transcriptional node whose output is set largely by how much coactivator is available and how active it is, rather than by the arrival of a circulating hormone. Energetic stress raises coactivator activity; coactivator activity drives ERR-dependent transcription; ERR-dependent transcription builds mitochondrial and oxidative capacity. Ranhotra's review adds a further wrinkle in the same direction, reporting that ERRα also controls PGC-1α expression — the relationship runs both ways.

The tissue distribution follows the function. A 2024 review in the International Journal of Molecular Sciences describes ERRα as the most extensively researched member of the family, holding a pivotal role in functions associated with energy metabolism, particularly in tissues with high energy requirements: heart, skeletal muscle, adipose tissue, kidney and brain. Those are precisely the tissues in which the SLU-PP-332 studies were run.

The transcriptional program ERRs govern

The reason an ERR agonist gets called an exercise mimetic at all is that the gene sets ERRs control overlap heavily with the gene sets that endurance training induces.

Broken into its components, the ERR-associated program covers mitochondrial biogenesis — making more mitochondria and more mitochondrial protein; oxidative phosphorylation — the electron transport chain machinery that converts substrate oxidation into ATP; fatty acid oxidation — the enzymes that route long-chain fats into β-oxidation; and the Krebs cycle enzymes that feed reducing equivalents into the chain. That four-part description is taken directly from how the Burris group's 2026 JPET paper characterises ERR target genes.

Endurance exercise induces a broadly similar shift. Repeated aerobic work increases mitochondrial content in trained muscle and moves substrate use toward fat oxidation. The 2023 ACS Chemical Biology paper that introduced SLU-PP-332 opens on exactly this point — that repetitive physical exercise induces physiological adaptations in skeletal muscle which improve exercise performance — and states that genetic evidence indicates the ERRs play an important role in skeletal muscle exercise capacity. That genetic argument is the intellectual foundation for the whole programme: if knocking ERRs out impairs the adaptation, then switching them on pharmacologically might drive it.

There is a specific and useful marker in this literature worth knowing about. The Burris group's 2026 paper reports that both SLU-PP-332 and its successor compound robustly induce expression of Ddit4, described there as a gene induced by acute aerobic exercise, with induction levels in mouse muscle matching or exceeding those produced by treadmill running depending on which muscle was examined. A 2026 systematic review in Revista Médica de Chile similarly identifies Ddit4 and Slc25a25 as markers of the acute aerobic exercise program that pan-ERR agonists induce, and describes the induction as ERRα-dependent.

Note the precision of the claim being made there. It is not “the compound produces the benefits of exercise.” It is “the compound induces a gene expression program resembling that induced by acute aerobic exercise.” Those are different statements, and the distance between them is the subject of the section on exercise mimetics below.

Where SLU-PP-332 came from

The SLU in the name is Saint Louis University, where Thomas Burris's laboratory did the medicinal chemistry. The compound was reported in 2023 in ACS Chemical Biology, with Cyrielle Billon as first author and a long collaborating list including Bahaa Elgendy, John Walker, Michael Downes and Ronald Evans.

The paper is explicit about the problem it set out to solve. Three ERR subtypes exist, and while ERRβ/γ agonists had been designed, the authors describe significant difficulties in designing compounds with ERRα agonist activity, and note that synthetic agonists usable to target ERRs in vivo were limited. SLU-PP-332 was reported as a synthetic pan agonist that targets all three subtypes with the highest potency for ERRα, and — the operative point for a research tool — with sufficient pharmacokinetic properties to be used as an in vivo chemical tool. The companion 2024 Circulation paper makes the same complaint from the cardiac side, stating that in vivo studies of ERR agonism for heart failure were lacking because compounds with pharmacokinetics appropriate for in vivo use had not been available.

That framing matters. SLU-PP-332 was built as a chemical probe — a tool for interrogating ERR biology in animals — not as a drug candidate. A 2026 structure–activity study in the International Journal of Biological Macromolecules describes it in exactly those terms: a well-established exercise mimetic and widely used chemical probe for ERR activation.

One consequence of the compound's small size and rational design is worth flagging for anyone reading vendor copy: it was designed to activate ERRs, and the catalogue description here notes it was intended to do so without cross-reactivity to the classical estrogen receptors. The Circulation group backed the specificity question with genetic dependency experiments rather than assertion, reporting that ERRγ was the main mediator of the transcriptional and cardioprotective effects in their model and describing that work as demonstrating target specificity.

What the published studies reported

The literature here is small and recent, and it is worth stating the size honestly. A PubMed search for “SLU-PP-332” run while writing this guide returned ten records. Every one of the in vivo studies among them is rodent work, and a substantial share of the total comes from the originating laboratory or its immediate collaborators.

The findings, reported in past tense and anchored to their models:

Two observations about this table that are easy to miss. The Bonanni pilot study is the only entry involving human material, and it is cell culture from surgical biopsies — myoblasts in a dish — not administration to anybody. And the 2026 Revista Médica de Chile systematic review, which surveyed this literature from 2020 to 2024, closes by stating that clinical trials are needed to confirm efficacy and safety in humans. That is the field's own summary of where it stands.

What “exercise mimetic” actually means

The phrase has a specific research meaning and a much looser popular one, and the gap between them is where most of the bad writing about this compound lives.

In the research sense, an exercise mimetic is a compound that activates signalling pathways downstream of exercise in order to reproduce some subset of exercise-induced adaptation. The 2021 Nature Reviews Drug Discovery review by Gubert and Hannan opens by describing exercise mimetics as a proposed class of therapeutics that specifically mimic or enhance the therapeutic effects of exercise — note “proposed.”

The term traces to a specific paper. In 2008, Narkar and colleagues published AMPK and PPARδ Agonists Are Exercise Mimetics in Cell, with Ronald Evans as senior author — the same Evans who appears on the 2023 SLU-PP-332 paper. The two compounds in that title were AICAR, an AMPK activator, and the PPARδ agonist GW1516, better known as GW501516 or cardarine. That paper effectively created the field.

It also created a problem, and the problem is instructive. Both AICAR and GW501516 moved rapidly out of the laboratory and into athletic misuse, and both ended up on anti-doping prohibited lists rather than in pharmacies. Neither became an approved medicine. That is the historical pattern any new exercise mimetic inherits: a striking rodent result, rapid uptake by people who are not researchers, and a regulatory response aimed at detection rather than approval.

Now the scientific objection, which is more fundamental than the regulatory one. Exercise is not a transcriptional event. Endurance training imposes mechanical loading on muscle, tendon and bone; it imposes cardiovascular and haemodynamic demand on the heart and vasculature; it produces thermoregulatory and endocrine responses; it involves motor learning and central neurological adaptation; it changes appetite, sleep and mood through routes that have nothing to do with any single nuclear receptor. A pan-ERR agonist reproduces a gene expression signature in metabolically active tissue. It does not load a tendon, it does not train a heart against afterload, and it does not put anything through a nervous system.

The honest version of the claim is therefore narrow: pan-ERR agonists have been reported to induce a transcriptional program overlapping with that induced by acute aerobic exercise in rodent muscle, and to shift some downstream physiological measures in the same direction in rodents. That is genuinely interesting. It is not “exercise in a pill,” and copy that says so is describing a marketing concept rather than a finding.

The field's own critical voices say something similar. A 2017 commentary in Clinical Pharmacology and Therapeutics titled Exercise Mimetics: Running Without a Road Map characterises exercise mimetics as bioactive compounds that activate signalling pathways to simulate exercise-like benefits, and notes that the case for them rests almost entirely on preclinical findings in rodents. Nearly a decade later, that sentence still describes SLU-PP-332 accurately.

Doping control, and why analysts are already looking

One of the clearest signals of where this compound sits is who is studying it. Two of the ten PubMed records for SLU-PP-332 are anti-doping analytical chemistry papers, both published in 2026, and both were written to make the compound detectable.

Avliyakulov, Sobolevsky and Ahrens, writing in Drug Testing and Analysis, state that the World Anti-Doping Agency prohibits the use of exercise mimetics and metabolic modulators in sport, and describe identification of SLU-PP-332 metabolites as a critical step towards detecting its misuse. Using pooled human liver S9 fractions and liquid chromatography–high-resolution mass spectrometry, they reported 22 metabolites: five monohydroxylated, three dihydroxylated, four reduced dihydroxylated species, plus direct glucuronidation and sulfation products and combinations of conjugation with hydroxylation on the naphthalene or phenolic rings. They note that further work is needed to fully elucidate the structures.

Möller, Krug and Thevis, in Rapid Communications in Mass Spectrometry, ran a parallel exercise on both SLU-PP-332 and its successor compound using human liver S9 fraction and human liver microsomes, identifying nine metabolites for SLU-PP-332 — six Phase I and three Phase II conjugates — with structural elucidation supported by NMR for selected species. Their stated purpose is to help uncover illicit use of these compounds as potential performance-enhancing substances.

Two things follow. First, these are in vitro metabolism studies using human liver preparations, not studies in which anyone was given the compound — a distinction that gets flattened in secondary write-ups. Second, the practical read is unambiguous: the analytical community treats SLU-PP-332 as a substance to be detected, and the metabolite maps needed to detect it now exist in the open literature. Anyone in a tested sport should read those two papers as what they are.

Pharmacology: the ceiling on this molecule

The most useful thing to understand about SLU-PP-332 is that its own developers have been steadily replacing it.

The 2023 paper introducing it described it as having pharmacokinetic properties sufficient to serve as an in vivo chemical tool — a deliberately modest claim, and a very different bar from “suitable for development.” The 2024 Circulation work introduced a second, structurally distinct pan-ERR agonist alongside it. The 2026 JPET paper is blunter still: it states that SLU-PP-332 improves aerobic performance in mice but lacks oral bioavailability, and presents the successor compound as chemically distinct, orally bioavailable, and comparably efficacious when exposure is accounted for.

The 2026 structure–activity paper points in the same direction from the chemistry side. Its stated result is that several analogues achieved comparable transcriptional responses while exhibiting improved ligand efficiency, solubility or metabolic stability — which is a polite way of saying the parent scaffold has liabilities on all three counts. The XLogP of 3.7 in the PubChem record is consistent with the solubility half of that.

One honest caveat on a commonly repeated claim. SLU-PP-332 is frequently described as having a short half-life. That is plausible given everything above — poor oral bioavailability, an extensive Phase I and Phase II metabolite map in human liver fractions, and successor compounds selected for metabolic stability — but no specific half-life figure appeared in any source retrieved for this guide, and this guide will not invent one. What the retrieved literature does support is the shape of the problem: this is a molecule that liver enzymes work on readily and that does not survive the oral route in the model species tested.

The other pharmacological limit is the one the compound class carries generally. There is no clinical development programme for SLU-PP-332 in the retrieved literature, no registered trial, and no regulatory approval anywhere. It is a research chemical and a chemical probe. Nothing in the file suggests it is on a path to becoming anything else — the succession of newer compounds suggests the opposite.

Handling a small molecule in a peptide catalogue

Because SLU-PP-332 is not a peptide, most of the standard peptide handling reflexes do not transfer. This section is generic and deliberately non-prescriptive — it describes how the chemistry differs, not what to do.

The practical consequences are straightforward. A compound with an XLogP near 4 will not simply dissolve in an aqueous diluent the way a short hydrophilic peptide does, and laboratories working with this chemical class generally prepare concentrated stocks in an organic solvent and dilute into assay buffer from there. Solutions of hydrazone-containing compounds are also worth characterising for stability rather than assumed, since the hydrazone linkage is a known site of pH-dependent hydrolysis in medicinal chemistry.

Storage differs too. The peptide storage guide and the site's notes on cold-chain handling are built around a lyophilised protein-like solid that is sensitive to moisture and to repeated freeze–thaw. A crystalline small-molecule solid is generally more robust than that, and the dominant concerns shift toward keeping it dry, dark and cool rather than toward cold-chain integrity specifically. Photostability is worth attention for a compound built from two conjugated aromatic systems joined by a C=N bond, since imine and hydrazone geometry can be light-sensitive.

On documentation, the same principle applies as everywhere else on the site, with one advantage: identity confirmation is easier for a small molecule than for a peptide. There is one exact mass to confirm and one HPLC peak to look at, with no sequence ambiguity to worry about. The certificate of analysis guide covers what to look for, and the reasoning is unchanged — purity by chromatography plus mass confirmation of identity, not one or the other. Materials for SLU-PP-332 are stocked here for laboratory use with COAs published where available.

For anyone mapping the wider mitochondrial and metabolic research space, the closest neighbour in the catalogue is MOTS-c, which approaches mitochondrial biology from the peptide side rather than the nuclear-receptor side and makes a useful contrast in both mechanism and evidence base.

What the evidence does not establish

This section matters more than usual here, because the gap between what was published and what gets said about it is unusually wide.

It does not establish anything in humans. There is no clinical trial of SLU-PP-332 in the retrieved literature. Every in vivo finding above — endurance, energy expenditure, fat oxidation, fat mass, insulin sensitivity, cardiac function — is from mice. The 2026 systematic review that surveyed this field says explicitly that clinical trials are needed to confirm efficacy and safety in humans. Rodent metabolic and cardiac models have a long history of not translating, and this compound has not been given the opportunity to fail that test yet.

It does not establish that a gene program equals a physiological outcome. The strongest and best-replicated claim in this file is transcriptional: the compound induces exercise-associated genes, including Ddit4, in an ERRα-dependent way. Inducing an adaptation-associated transcriptional signature is not the same as producing the adaptation, and it is emphatically not the same as producing the whole-organism consequences of training.

It does not establish independence from the originating group. The literature is small — ten PubMed records — and the core in vivo findings cluster around the Burris laboratory and its collaborators. The Bonanni myoblast pilot and the two anti-doping analytical papers are genuinely independent, but none of those tested the endurance or body-composition claims. Independent replication of the central in vivo results by an unaffiliated laboratory is not present in the retrieved record.

It does not establish sample sizes worth leaning on. The one study using human-derived material enrolled 20 women and derived myoblast cultures from the 10 inactive participants, and its own authors describe it as a pilot and call for further work to clarify the molecular mechanisms involved.

It does not establish a safety profile. The 2026 systematic review describes preclinical metabolic effects as occurring “without evident toxicity,” which is a statement about short rodent studies, not a safety dataset. There is no human safety data of any kind. There is no long-term rodent data. And there is a specific unexamined question sitting in plain view: ERRα appears in the cancer literature as well as the metabolism literature — Ranhotra's 2015 review notes its regulatory networks have important consequences including in the development of cancer — and nothing in the retrieved SLU-PP-332 file addresses long-horizon consequences of chronic pan-ERR activation.

It does not establish a pharmacokinetic profile suitable for anything but bench work. The compound's own developers report it lacks oral bioavailability and have moved to structurally distinct successors selected for oral activity and metabolic stability. Treat SLU-PP-332 as what it was designed to be: a chemical probe.

It does not establish anything about human outcomes from any product sold on this site. SLU-PP-332 is not an approved drug and is stocked here for laboratory research only.

Frequently asked questions

Is SLU-PP-332 a peptide? No. The PubChem record gives C₁₈H₁₄N₂O₂, a molecular weight of about 290.3, and the name 4-hydroxy-N-[(E)-naphthalen-2-ylmethylideneamino]benzamide. No amino acids, no sequence, no peptide chain. It is an acylhydrazone — a small organic molecule — and it appears alongside peptides because of the research area it belongs to, not its chemistry.

What does the SLU in the name mean? Saint Louis University, where Thomas Burris's laboratory carried out the medicinal chemistry. The compound was reported in ACS Chemical Biology in 2023 with Cyrielle Billon as first author.

Why are they called estrogen-related receptors if estrogen does not activate them? The name records sequence similarity to the classical estrogen receptor, not a shared ligand. ERRα, ERRβ and ERRγ are classified as orphan nuclear receptors, and a 2015 review in the Journal of Receptor and Signal Transduction Research states that it is presently unknown which endogenous hormones or ligands activate ERRα. Their transcriptional output is described as being set largely by coactivators, principally PGC-1α.

What did the mouse studies actually report? The 2023 ACS Chemical Biology paper reported increased mitochondrial function and cellular respiration in a skeletal muscle cell line, and in mice, increased type IIa oxidative fibres, enhanced exercise endurance, and induction of an ERRα-specific acute aerobic exercise gene program. A 2024 JPET paper in diet-induced obese and ob/ob mice reported increased energy expenditure and fatty acid oxidation with decreased fat mass accumulation. A 2024 Circulation paper reported improved ejection fraction, reduced fibrosis and increased survival in a pressure overload heart failure model, with ERRγ identified as the main mediator.

Is there any human data? None from administration to people. The only human-derived work retrieved is a 2025 pilot study in Frontiers in Physiology that treated cultured myoblasts isolated from muscle biopsies of ten inactive women. The two anti-doping papers used human liver S9 fractions and microsomes — laboratory preparations, not subjects. A 2026 systematic review states clinical trials are needed to confirm efficacy and safety in humans.

Is it really “exercise in a pill”? No, and the phrase should be retired. A pan-ERR agonist induces a transcriptional program overlapping with the one acute aerobic exercise induces. Exercise also imposes mechanical loading, cardiovascular demand, thermoregulatory and endocrine responses and central neurological adaptation, none of which follow from activating a nuclear receptor. A 2017 commentary in Clinical Pharmacology and Therapeutics notes the field rests almost entirely on preclinical rodent findings. On top of which, SLU-PP-332 was reported in 2026 as lacking oral bioavailability in mice — so even the “pill” half of the phrase is inaccurate for this particular molecule.

Is SLU-PP-332 approved for human use? No. It is sold strictly for in-vitro research and laboratory use only. It is not an approved drug, there is no clinical development programme for it in the retrieved literature, and it is not intended for human or veterinary consumption. A 2026 paper in Drug Testing and Analysis notes that the World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators in sport, and describes metabolite identification work undertaken specifically so that misuse can be detected.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.